Apertura Gene Therapy Launches Open Aperture Program to Democratize Access to CNS-Targeting AAV Capsid
Key Insights
Apertura Gene Therapy (search) launched Open Aperture, a material transfer agreement program providing no-cost access to TfR1 CapX (search), a leading AAV capsid for CNS gene therapy (search) research.
TfR1 CapX (search) leverages human transferrin receptor 1 (search) to enable intravenous delivery across the blood-brain barrier, representing the first successful AAV capsid targeting of hTfR1 (search).
The program aims to accelerate CNS gene therapy (search) development by democratizing access for qualified academic researchers at accredited institutions.
Apertura Gene Therapy (search) announced the launch of Open Aperture, a material transfer agreement program that provides qualified academic researchers with no-cost access to TfR1 CapX (search), a leading adeno-associated virus (AAV) capsid designed for central nervous system gene therapy applications. The program aims to democratize access to clinically relevant capsids for academic researchers conducting non-commercial research at accredited institutions.
Revolutionary CNS-Targeting Technology
TfR1 CapX (search) represents a significant advancement in gene therapy delivery systems, engineered to bind to human transferrin receptor 1 (search) (hTfR1 (search)) with the goal of transporting genetic medicines across the blood-brain barrier and achieving broad distribution throughout the CNS. Leveraging a platform developed by the Deverman Lab at the Broad Institute (search) of Harvard and MIT, Apertura has become the first biotech company to successfully target hTfR1 with an AAV capsid.
The capsid utilizes a well-characterized BBB-shuttling mechanism that has been investigated by industry and academia for more than 40 years. According to the company, one approved therapy and several clinical-stage programs already benefit from an understanding of hTfR1 (search) biology, providing a strong foundation for the technology's clinical application.
Addressing Academic Research Barriers
"Academic labs are doing important early work in CNS gene therapy (search), but progress can be slowed or even stopped when attempts to gain access to clinically relevant capsids are unsuccessful," said Dave Greenwald, Ph.D., Managing Director at Deerfield Management (search) and Executive Chairperson of the Board of Directors at Apertura. "Since there are far more promising payload ideas than any one research team can pursue, one exciting way to expedite the development of genetic medicines is to enable work across the academic research community by expanding access to capsids."
The Open Aperture program offers several key benefits including no-cost capsid access for eligible academic laboratories, a streamlined online application process, practical guidance on chemistry, manufacturing, and controls (CMC) and preclinical development, and introductions to third-party CMC vendors and contract research organizations (CROs) experienced with TfR1 CapX (search).
Clinical Readiness and Validation
TfR1 CapX (search) is positioned as a proprietary, second-generation capsid that demonstrates superior CNS delivery compared to Apertura's first-generation capsid, BI-hTFR1 (search). Multiple for-profit and non-profit organizations have validated TfR1 CapX and are in discussions to license the technology.
Apertura is preparing TfR1 CapX (search) for use in clinical studies, with programs using the capsid expected to enter the clinic this year and next. This timeline positions TfR1 CapX as a leading IV-administered, BBB-crossing capsid. Clinical readiness is supported by preclinical development, regulatory engagement, and established manufacturing by contract development and manufacturing organizations (CDMOs).
Company Background
Founded in 2021 on technology from the Broad Institute (search) and supported by Deerfield Management (search) Company, Apertura Gene Therapy (search) develops genetic medicines and next-generation AAV capsids that precisely engage human-relevant receptors. The company has licensed its next-generation capsids to multiple partners, with programs expected to enter clinical trials this year and next year.